China, Zai Lab and Vyvgart Hytrulo
Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...
Analyst Jonathan Chang from Leerink Partners reiterated a Buy rating on Zai Lab (ZLAB – Research Report) and keeping the price target at ...
Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug that it ...
Just a few months into a new launch in chronic inflammatory demyelinating polyneuropathy (CIDP), agrenx’ Vyvgart is already making headway in the rare disease space, just one of the long-term growt | ...
with continued momentum in both Vyvgart and Vyvgart Hytrulo. Following Vyvgart's approval in both intravenous and subcutaneous formats for MG in the US, Argenx is actively expanding its ...
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2024, along with recent product highlights and corporate ...
VYVGART and its subcutaneous formulation, VYVGART Hytrulo, have been the primary drivers of argenx's success. Global net sales for these products reached approximately $398 million in the first ...
VYVGART Hytrulo is approved for CIDP as a once weekly 30-to-90 second subcutaneous injection. It is the first and only therapy approved in China for the treatment of CIDP, a debilitating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback